Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Operations: 2020-2024

Historic Cash from Operations for Journey Medical (DERM) over the last 5 years, with Dec 2024 value amounting to -$9.1 million.

  • Journey Medical's Cash from Operations fell 105.96% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.9 million, marking a year-over-year increase of 85.89%. This contributed to the annual value of -$9.1 million for FY2024, which is 274.18% down from last year.
  • Per Journey Medical's latest filing, its Cash from Operations stood at -$9.1 million for FY2024, which was down 274.18% from $5.2 million recorded in FY2023.
  • Journey Medical's Cash from Operations' 5-year high stood at $5.2 million during FY2023, with a 5-year trough of -$13.5 million in FY2022.
  • Its 3-year average for Cash from Operations is -$5.8 million, with a median of -$9.1 million in 2024.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 520.54% in 2022, then soared by 138.72% in 2023.
  • Over the past 5 years, Journey Medical's Cash from Operations (MRY) stood at $5.1 million in 2020, then plummeted by 142.50% to -$2.2 million in 2021, then tumbled by 520.54% to -$13.5 million in 2022, then skyrocketed by 138.72% to $5.2 million in 2023, then crashed by 274.18% to -$9.1 million in 2024.
  • Its last three reported values are -$9.1 million in FY2024, $5.2 million for FY2023, and -$13.5 million during FY2022.